TMPRSS2 and prostate carcinoma: It is expressed highly in prostate cancer (Lin et al., 1999; Lucas et al., 2008) (for review, see Tanabe & List, 2017) and loss of TMPRSS2 in the prostate is associated with reduced metastatic potential (Lucas et al., 2014).